Bevacizumab-induced nasal septum perforation.
Fakih
Marwan G
MG
Lombardo
Jeffrey C
JC
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068258:Bevacizumab; D006801:Humans; D008297:Male; D008875:Middle Aged; D009300:Nasal Septum; D009668:Nose Diseases / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab